NATCO launches Bosentan Tablets for Oral Suspension in the United States with 180-day exclusivity
NATCO Pharma Limited (BSE: 524816 and NSE: NATCOPHARM) (“NATCO”) today announced the launch of Bosentan tablets for oral suspension (TFOS), 32mg, a generic version of Tracleer® by Actelion Pharmaceuticals US Inc. NATCO’s marketing partner for …

